ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.
Equities
IPA
CA45257F2008
Pharmaceuticals
Sales 2024 * | 24.59M 17.97M | Sales 2025 * | 29.82M 21.8M | Capitalization | 47.55M 34.76M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.77M | Net income 2025 * | -9M -6.58M | EV / Sales 2024 * | 1.93 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.59 x |
P/E ratio 2024 * |
-3.76
x | P/E ratio 2025 * |
-5.1
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |